Cutera Yönetim

Yönetim kriter kontrolleri 0/4

Cutera CEO'su Taylor Harris, Aug2023 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı $ 7.69M olup, şirket hissesi ve opsiyonları dahil olmak üzere 3.5% maaş ve 96.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.44% ine doğrudan sahiptir ve bu hisseler € 26.83K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 1.5 yıldır.

Anahtar bilgiler

Taylor Harris

İcra Kurulu Başkanı

US$7.7m

Toplam tazminat

CEO maaş yüzdesi	3.5%
CEO görev süresi	1.3yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	1.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Taylor Harris'un ücretlendirmesi Cutera'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$144m
Jun 30 2024	n/a	n/a	-US$149m
Mar 31 2024	n/a	n/a	-US$158m
Dec 31 2023	US$8m	US$271k	-US$163m

Tazminat ve Piyasa: Taylor 'nin toplam tazminatı ($USD 7.69M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 471.55K ).

Tazminat ve Kazançlar: Taylor şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Taylor Harris (48 yo)

1.3yrs

Görev süresi

US$7,685,535

Tazminat

Mr. Taylor C. Harris serves as Director of Omada Health, Inc. since February 2022. He serves as Advisor at Lauxera Capital Partners. Mr. Harris has been an Independent Director at HealthCor Catalio Acquisi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Taylor Harris	President	1.3yrs	US$7.69m	0.44% € 26.8k
Stuart Drummond	Chief Financial Officer	1.5yrs	US$777.83k	0.088% € 5.4k
Jeffrey Jones	Chief Operating Officer	1.3yrs	US$541.00k	Veri yok
Stephana Patton	Chief Legal Officer	less than a year	US$347.73k	0.020% € 1.2k
Charles Thier	Chief Information Officer	5.1yrs	US$1.86m	Veri yok
Greg Barker	Vice President of FP&A and Investor Relations	no data	Veri yok	Veri yok
Steve Kreider	Senior Vice President of Global Marketing	2.8yrs	Veri yok	Veri yok
Brent Hauser	President of International	1.1yrs	Veri yok	Veri yok
Shelby Eckerman	Vice President of Finance	no data	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: TJ9 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Taylor Harris	President	1.5yrs	US$7.69m	0.44% € 26.8k
Jeryl Hilleman	Director	less than a year	Veri yok	Veri yok
Kevin Cameron	Independent Chairman	1.5yrs	US$285.40k	Veri yok
Keith Sullivan	Independent Director	1.5yrs	US$220.05k	0.020% € 1.2k
Nicholas Lewin	Independent Director	1.5yrs	US$268.79k	Veri yok

1.5yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TJ9 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Cutera Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

High number of new and inexperienced directors

Cutera, Inc., Annual General Meeting, Jul 15, 2024

High number of new and inexperienced directors

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

Recent updates

Cutera Receives Deficiency Notice from Nasdaq Regarding Minimum $15 Million Market Value of Publicly Held Shares Requirement under Nasdaq Marketplace Rule 5450(b)(3)(C)

New major risk - Market cap size

Cutera, Inc. Reaffirms Financial Guidance for the Full Year 2024

Cutera, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1)

Second quarter 2024 earnings released: US$1.23 loss per share (vs US$1.68 loss in 2Q 2023)

Cutera, Inc. Revises Revenue Guidance for the Year 2024

High number of new and inexperienced directors

Cutera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cutera, Inc.(NasdaqGS:CUTR) dropped from Russell 3000 Index

High number of new and inexperienced directors

Cutera, Inc., Annual General Meeting, Jul 15, 2024

Cutera, Inc. Reiterates Earnings Guidance for 2024

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Cutera, Inc. Announces North America Launch of xeo+

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Cutera, Inc. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$2.22 loss per share (vs US$0.62 loss in 3Q 2022)

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

High number of new and inexperienced directors

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q

Cutera, Inc. announced delayed 10-Q filing

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

New minor risk - Market cap size

Cutera, Inc. Appoints Brent Hauser as President, International

Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO

President recently bought €274k worth of stock

Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023

Second quarter 2023 earnings released: US$1.59 loss per share (vs US$2.53 loss in 2Q 2022)

Cutera, Inc. Provides Revenue Guidance for the Full Year 2023

Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023

Cutera, Inc. Announces CEO Changes, Effective August 7, 2023

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023

Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris

Cutera, Inc. Announces Resignation of J. Daniel Plants as Director

Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc

Less than half of directors are independent

Cutera, Inc. Announces Board Changes

Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer

Voce Capital and David Mowry Terminate Proxy Solicitation

Cutera, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$1.27 loss per share (vs US$0.84 loss in 1Q 2022)

Full year 2022 earnings released: US$4.39 loss per share (vs US$0.12 profit in FY 2021)

Now 26% undervalued after recent price drop

Full year 2022 earnings released: US$4.39 loss per share (vs US$0.12 profit in FY 2021)

Cutera, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Cutera, Inc. Announces AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.077 loss in 3Q 2021)

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Cutera, Inc. Announces Committee Appointments

Cutera, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Cutera, Inc. Announces Resignation of Katherine S. Zanotti from the Board

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$2.53 loss per share (vs US$0.43 profit in 2Q 2021)

Cutera, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cutera, Inc. Announces AviClear Secured Clearance from Health Canada

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.02 loss in 1Q 2021)

Cutera, Inc., Annual General Meeting, Jun 15, 2022

Cutera Announces First Patient Treated with FDA Cleared Aviclear Acne Device

High number of new directors

CEO & Director recently bought €92k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cutera, Inc. Provides Revenue Guidance for the Year 2022